ADVANCED SOLID TUMOR

This early-phase study tests a new drug called M9466, alone or with other treatments, in people with advanced solid tumors that have not responded to standard therapy. The main goal is to check safety and how the drug moves through the body. About 141 participants will receive th…

This study is testing an experimental drug called LM-108, given alone or with other cancer treatments, in about 392 people with advanced solid tumors that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose, and to see i…

This early-phase study tests an experimental tablet called BB3008 in about 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety, find the best dose, and see how food affects it. Participants take the pill by m…

This early-phase study tests an experimental drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body processes the drug. About 222 people with lung, colorectal, or pancreatic cancer th…

This early-stage study tests a new drug called PRJ1-3024 in about 39 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug migh…

This early-phase trial tests a new drug called DM919, given alone or with another drug (pembrolizumab), in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe and effective dose and see if it can shrink tumors. Participants…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This study tests an experimental drug called TransCon IL-2 β/γ, which is designed to boost the immune system's ability to fight advanced solid tumors. About 320 adults with cancers like ovarian, melanoma, lung, or cervical cancer will receive the drug alone or combined with other…

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have a protein called Nectin-4. The goal is to see if the drug is safe and shrinks tumors. About 329 adults with cancers like bladder, breast, lung, or…

This study tests a new drug called JSKN003 in Chinese adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 725 participants will receive the drug by IV every three weeks.

This study tests a new drug called DB-1305 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 1,100 adults will take part in this early-phase trial.

This study tests a new experimental drug called ANV600, given alone or with another drug (pembrolizumab), in 240 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety and see if the drug shrinks tumors. This is an early-…

This early-stage study tests two drugs, niraparib and neratinib, together in people with advanced solid tumors or ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find the safest dose and see if the combination can stop the cancer from growing for a…

This study tests an experimental drug called KL590586 in people with advanced solid tumors that have a specific change in the RET gene. The goal is to see if the drug is safe and can shrink tumors. About 414 adults whose cancer has not responded to standard treatments will take t…

This early-phase study tests a new drug called BGB-C354, which delivers a cancer-killing agent directly to tumor cells, alone or with an immunotherapy (tislelizumab). The goal is to find a safe dose and see if it shrinks tumors in people with advanced solid cancers that have not …

This study is testing an experimental drug called MHB039A in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective. About 196 participants will receive the drug, and researchers will monitor side eff…

This early-stage trial tests a new drug called SON-1010 in about 42 adults with advanced solid tumors that have spread. The main goals are to check the drug's safety and find the highest dose that can be given without causing severe side effects. Researchers will also measure how…

This early-phase trial tests a combination of three common drugs—metformin, digoxin, and simvastatin—in people with advanced pancreatic cancer or other solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 people will take par…

This early-stage study tests a new drug called TORL-3-600 in 70 adults with advanced solid tumors or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also see if the drug can shrink tumors or slow cancer growth.

This early-stage study tests an experimental drug called BGB-15025, either alone or with an immunotherapy drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if t…

This early-phase study tests a new oral drug, MOMA-313, alone or with another drug (olaparib) in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check its safety. Participants have specific cancers like liver cancer or melanoma that cannot…

This study tests a new drug called vilastobart, alone or with another drug (atezolizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors. About 136 adults with various advanced can…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This study tests a new drug called ZG005 in 50 adults with advanced solid tumors that did not respond to or could not tolerate standard treatments. The main goal is to see if the drug shrinks tumors and to check for side effects. Participants receive the drug and are monitored cl…

This study tests a new drug called MHB036C in 200 adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will be closely monitored for side effects.

This study tests an experimental oral drug called IMM-1-104 in people with advanced solid tumors that have RAS mutations. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 209 adults with certain cancers like pancreatic, melanoma, or lu…

This study tests an experimental pill called ATRN-119 in people with advanced solid tumors that have certain DNA repair mutations. The goal is to see if the drug is safe and can shrink tumors. About 132 participants will take the drug by mouth, and researchers will monitor side e…

This study tests an experimental drug called TTX-MC138 in 16 adults with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety and see if it can shrink or stabilize tumors. Participants receive increasing doses to find the be…

This early-stage study tests a new drug called CLN-619, given alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. About 440 peopl…

This study tests a new drug called LP-184 in people with advanced solid tumors (like certain breast, lung, or pancreatic cancers) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 64 participan…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This early-phase study tests an experimental drug called RP3, alone or with an immunotherapy (PD-1 blocker), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 123 people will take pa…

This study tests a new drug called NUV-1511 in people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors in specific cancers like breast, prostate, pancreatic…

This study tests a new drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to find the best dose and see if it shrinks tumors or slows disease. Participants must have tried other treatments and have measurable tumors.

This study tests a new drug called BT7480, alone or with another drug (nivolumab), in about 200 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors or slows cancer growth. Participant…

This early-phase study tests a new treatment called KSQ-001EX for people with advanced solid tumors (melanoma, lung, or head/neck cancers) that have not responded to standard therapy. The treatment involves taking a patient's own tumor-fighting immune cells, modifying them in a l…

This early-phase study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and how the body processes it. Participants receive the drug until their disease worsens or s…

This early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for signs that the drug sh…

This early-stage study tests a new drug called TORL-2-307-ADC in 163 people with advanced solid tumors, including stomach, pancreas, and esophageal cancers. The main goals are to find a safe dose and check for side effects. Researchers will also see if the drug can shrink tumors …

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…

This early-phase study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking at whe…

This study tests a drug called erdafitinib in people with advanced solid tumors that have certain changes in FGFR genes. The goal is to see if the drug can shrink tumors. The study includes both adults and children who have already tried other treatments or have no standard optio…

This study looks at whether a simple blood test (liquid biopsy) can be used during regular care for people with advanced solid tumors. The test measures tumor DNA in the blood to track the cancer and find genetic changes that may guide treatment. About 159 patients will participa…

This study tests whether rituximab or tocilizumab can help people with advanced solid tumors stop using steroids for immune-related side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can discontinue steroids within 4 weeks. T…

This study tests a program called Meaning-Centered Pain Coping Skills Training (MCPC) for people with advanced solid tumor cancer who have pain. The program teaches skills to manage pain and its impact on daily life. About 211 participants will either receive MCPC or standard car…